ELISA Kit for Synaptophysin (SYP)
Major synaptic vesicle protein p38
- UOM
- FOB US$ 479.00 US$ 684.00 US$ 3,078.00 US$ 5,814.00 US$ 47,880.00
- Quantity
Overview
Properties
- Product No.CEA425Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- ApplicationsEnzyme-linked immunosorbent assay for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryNeuro science
Sign into your account
Share a new citation as an author
Upload your experimental result
Review

Contact us
Please fill in the blank.
Recovery
Matrices listed below were spiked with certain level of recombinant Synaptophysin (SYP) and the recovery rates were calculated by comparing the measured value to the expected amount of Synaptophysin (SYP) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 79-93 | 83 |
EDTA plasma(n=5) | 92-104 | 101 |
heparin plasma(n=5) | 98-105 | 102 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Synaptophysin (SYP) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Synaptophysin (SYP) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Synaptophysin (SYP) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 80-93% | 81-104% | 91-101% | 80-104% |
EDTA plasma(n=5) | 78-102% | 93-102% | 81-101% | 80-94% |
heparin plasma(n=5) | 98-105% | 88-102% | 80-89% | 85-95% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well.
And then add 50µL prepared Detection Reagent A immediately.
Shake and mix. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
5. Aspirate and wash 5 times;
6. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
7. Add 50µL Stop Solution. Read at 450 nm immediately.

Test principle
This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Synaptophysin (SYP) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Synaptophysin (SYP) and unlabeled Synaptophysin (SYP) (Standards or samples) with the pre-coated antibody specific to Synaptophysin (SYP). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Synaptophysin (SYP) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Synaptophysin (SYP) in the sample.
Giveaways
Increment services
Citations
- Increased Amyloid-β Peptide-Induced Memory Deficits in Phospholipid Transfer Protein (PLTP) Gene Knockout MiceNature: Source
- BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS Read more: http://www.faqs.org/patents/app/20130090307#ixzz3VGRXUqW9Faqs:Source
- In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Diseasepubmed:27609215
- An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's …articles:journal-of-alzheimers-disease
- Investigating the roles of SRRM4 in contribution to neuroendocrine prostate cancer progression
- Neuroprotection in non-transgenic and transgenic mouse models of Alzheimer's disease by positive modulation of σ1 receptorsPubmed: 31048034
- Fermented Goat Milk Consumption Enhances Brain Molecular Functions during Iron Deficiency Anemia RecoveryPubmed: 31591353
- Tunable Substrate Functionalities Direct Stem Cell Fate toward Electrophysiologically Distinguishable Neuron-like and Glial-like Cells33356098
- Enriched Environment Minimizes Anxiety/Depressive-Like Behavior in Rats Exposed to Immobilization Stress and Augments Hippocampal Neurogenesis (In Vitro)33492617